Zhe Zhang1, Hongyan Mao2, Xingwen Wang1, Wei Sheng2. 1. Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. 2. Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Abstract
OBJECTIVE: The objective of the study is to compare computed tomography (CT)-based I125 radioactive seed brachytherapy (RSB) joint three-dimensional conformal radiotherapy (3D-CRT) and stereotactic ablative radiotherapy (SBRT) on early nonsmall cell lung cancer (NSCLC). METHODS: The study involved 30 Stage I and II NSCLC patients from March 2014 to June 2017. The patients were divided into two groups: 20 cases with CT-based RSB-3D-CRT (300 cGy × 10) (Group A) and 10 cases with SBRT (8 cGy × 6) (Group B). Their local control rates, 1-year survival rates, and toxic and side effects were compared. RESULTS: The median time of follow-up was 20 months (3-51 months). The 1-year local control rate in Groups A and B was 90% and 80%, respectively (P = 0.70). The 1-year survival rate in Groups A and B was 90% and 90%, respectively (P = 1.00). The indicator of radioactive pneumonia V20 and V30 in Groups A and B was 6.06% and 4.207%, and 11.32% and 7.111%, respectively (P = 0.000024 and 0.00090). CONCLUSION: Compared with SBRT, RSB-3D-CRT was more aggressive on early NSCLC. It remarkably reduced the indicators (V20 and V30) and the incidence of radioactive pneumonia.
OBJECTIVE: The objective of the study is to compare computed tomography (CT)-based I125 radioactive seed brachytherapy (RSB) joint three-dimensional conformal radiotherapy (3D-CRT) and stereotactic ablative radiotherapy (SBRT) on early nonsmall cell lung cancer (NSCLC). METHODS: The study involved 30 Stage I and II NSCLC patients from March 2014 to June 2017. The patients were divided into two groups: 20 cases with CT-based RSB-3D-CRT (300 cGy × 10) (Group A) and 10 cases with SBRT (8 cGy × 6) (Group B). Their local control rates, 1-year survival rates, and toxic and side effects were compared. RESULTS: The median time of follow-up was 20 months (3-51 months). The 1-year local control rate in Groups A and B was 90% and 80%, respectively (P = 0.70). The 1-year survival rate in Groups A and B was 90% and 90%, respectively (P = 1.00). The indicator of radioactive pneumonia V20 and V30 in Groups A and B was 6.06% and 4.207%, and 11.32% and 7.111%, respectively (P = 0.000024 and 0.00090). CONCLUSION: Compared with SBRT, RSB-3D-CRT was more aggressive on early NSCLC. It remarkably reduced the indicators (V20 and V30) and the incidence of radioactive pneumonia.